Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Solabegron (GW427353)
Solabegron · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Solabegron | DRUG | - |
| solabegron and oxybutynin | DRUG | - |
| Placebo | DRUG | - |
| Solabegron (GW427353) | DRUG | - |
Inclusion Criteria: * Overactive bladder with symptoms of urgency with urge incontinence and frequency which may be associated with nocturia but without bladder pain. * Body mass index in the range of = 19 kg/m2 to \<35 kg/m2. Exclusion Criteria: * Pregnant * Of childbearing potential or willing ...
Solabegron is an investigational small molecule developed by GSK plc for irritable bowel syndrome and overactive bladder. It is a beta-3 adrenergic receptor agonist that has been studied in Phase 1 and Phase 2 clinical trials. It is not approved for any indication and remains in clinical development.
Solabegron has been studied for the treatment of overactive bladder symptoms. A Phase 2 dose-ranging trial evaluated solabegron versus placebo in female patients with overactive bladder. It is investigational and has not been approved for this or any other use.
Solabegron targets the beta-3 adrenergic receptor, also known as ADRB3. It acts as an agonist at this receptor. This mechanism has been explored in conditions such as overactive bladder and irritable bowel syndrome.
Solabegron is being developed by GSK plc, which trades under the ticker GSK. The company has sponsored clinical trials of solabegron in overactive bladder and irritable bowel syndrome.
Solabegron is in Phase 1 clinical development according to the available data, though a Phase 2 trial has also been completed. It is investigational and has not received FDA approval. Further development status has not been disclosed.
Solabegron has been studied in completed trials including NCT00501267, NCT00427596, NCT00401479, and NCT00343486. These trials evaluated drug interactions, formulation, gastrointestinal transit, and dose-ranging in overactive bladder and irritable bowel syndrome. No active trials are currently listed.
Yes, solabegron is also known as GW427353. The combination of solabegron and oxybutynin has also been referred to in study contexts. Solabegron is the primary name used for this investigational drug.